Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype
BackgroundMetaplastic breast cancer (MBC) is a rare and aggressive subtype of the breast. To understand the characteristics and prognosis of single hormone receptor-positive (HR+) MBC (estrogen receptor-positive [ER+]/progesterone receptor-negative [PR-] and ER-/PR+), we compared these tumors to dou...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-04-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.628939/full |
| _version_ | 1818934074263207936 |
|---|---|
| author | Jinqian Mao Jin Hu Yanting Zhang Jian Shen Fang Dong Ximeng Zhang Jie Ming Tao Huang Xiaoqin Run |
| author_facet | Jinqian Mao Jin Hu Yanting Zhang Jian Shen Fang Dong Ximeng Zhang Jie Ming Tao Huang Xiaoqin Run |
| author_sort | Jinqian Mao |
| collection | DOAJ |
| description | BackgroundMetaplastic breast cancer (MBC) is a rare and aggressive subtype of the breast. To understand the characteristics and prognosis of single hormone receptor-positive (HR+) MBC (estrogen receptor-positive [ER+]/progesterone receptor-negative [PR-] and ER-/PR+), we compared these tumors to double HR+ tumors as well as HR- tumors.Patients and MethodsThe Surveillance, Epidemiology, and End Results database was used to analyze MBC between 1975 and 2016. The effect of HR status was evaluated using a multivariate Cox regression model.ResultsWe included 3369 patients with a median follow-up time of 42 months (range 0-322 months). In this study, 280 (8.3%) cases were double HR+ tumors, 2597 (77.1%) were double HR- tumors, and 492 (14.6%) cases were single HR+ tumors, of which 159 (4.7%) cases were ER-/PR+ tumors and 333 (9.9%) were ER+/PR- tumors. On multivariate Cox analysis, the prognosis was related to age, race/ethnicity, tumor grade, TNM stage, and surgery. HR status remained no impact on breast cancer-specific survival (BCSS). In the Kaplan-Meier curve, HR status was not associated with better BCSS or overall survival (OS). In patients without HER2 overexpression, the BCSS and OS of ER+/PR- and ER-/PR+ tumors were not significantly different from that of ER-/PR- and ER+/PR+ tumors. The difference remains no significant in patients with HER2 overexpression.ConclusionsIn comparison with both ER-/PR- and ER+/PR+ tumors, we have identified clinically and biologically distinct features of single HR+ tumors. In patients with or without HER2 overexpression, the prognosis of single HR+ tumors was similar to ER-/PR- and ER+/PR+ tumors. |
| first_indexed | 2024-12-20T04:58:29Z |
| format | Article |
| id | doaj.art-ba514709fb8344ce805dd823103cd073 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-20T04:58:29Z |
| publishDate | 2021-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-ba514709fb8344ce805dd823103cd0732022-12-21T19:52:38ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922021-04-011210.3389/fendo.2021.628939628939Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative SubtypeJinqian Mao0Jin Hu1Yanting Zhang2Jian Shen3Fang Dong4Ximeng Zhang5Jie Ming6Tao Huang7Xiaoqin Run8Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaBackgroundMetaplastic breast cancer (MBC) is a rare and aggressive subtype of the breast. To understand the characteristics and prognosis of single hormone receptor-positive (HR+) MBC (estrogen receptor-positive [ER+]/progesterone receptor-negative [PR-] and ER-/PR+), we compared these tumors to double HR+ tumors as well as HR- tumors.Patients and MethodsThe Surveillance, Epidemiology, and End Results database was used to analyze MBC between 1975 and 2016. The effect of HR status was evaluated using a multivariate Cox regression model.ResultsWe included 3369 patients with a median follow-up time of 42 months (range 0-322 months). In this study, 280 (8.3%) cases were double HR+ tumors, 2597 (77.1%) were double HR- tumors, and 492 (14.6%) cases were single HR+ tumors, of which 159 (4.7%) cases were ER-/PR+ tumors and 333 (9.9%) were ER+/PR- tumors. On multivariate Cox analysis, the prognosis was related to age, race/ethnicity, tumor grade, TNM stage, and surgery. HR status remained no impact on breast cancer-specific survival (BCSS). In the Kaplan-Meier curve, HR status was not associated with better BCSS or overall survival (OS). In patients without HER2 overexpression, the BCSS and OS of ER+/PR- and ER-/PR+ tumors were not significantly different from that of ER-/PR- and ER+/PR+ tumors. The difference remains no significant in patients with HER2 overexpression.ConclusionsIn comparison with both ER-/PR- and ER+/PR+ tumors, we have identified clinically and biologically distinct features of single HR+ tumors. In patients with or without HER2 overexpression, the prognosis of single HR+ tumors was similar to ER-/PR- and ER+/PR+ tumors.https://www.frontiersin.org/articles/10.3389/fendo.2021.628939/fullmetaplastic breast cancerhormonal receptorHER2prognosisSEER database |
| spellingShingle | Jinqian Mao Jin Hu Yanting Zhang Jian Shen Fang Dong Ximeng Zhang Jie Ming Tao Huang Xiaoqin Run Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype Frontiers in Endocrinology metaplastic breast cancer hormonal receptor HER2 prognosis SEER database |
| title | Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype |
| title_full | Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype |
| title_fullStr | Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype |
| title_full_unstemmed | Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype |
| title_short | Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype |
| title_sort | single hormone receptor positive metaplastic breast cancer similar outcome as triple negative subtype |
| topic | metaplastic breast cancer hormonal receptor HER2 prognosis SEER database |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2021.628939/full |
| work_keys_str_mv | AT jinqianmao singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT jinhu singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT yantingzhang singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT jianshen singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT fangdong singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT ximengzhang singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT jieming singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT taohuang singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype AT xiaoqinrun singlehormonereceptorpositivemetaplasticbreastcancersimilaroutcomeastriplenegativesubtype |